Rilzabrutinib治疗温抗体型自身免疫性溶血性贫血的2b期研究
LUMINA 2是一项多中心、单臂、开放标签2b期研究,评估口服BTK抑制剂rilzabrutinib(伴或不伴糖皮质激素)在成人温抗体型自身免疫性溶血性贫血中的安全性和活性。A部分22例中14例(64%;95%CI 41-83)达总体血红蛋白应答,B部分15例中12例(80%)达持久应答;治疗相关不良事件A部分10例(45%)、B部分4例(27%),无导致停药的不良事件或死亡。
要点
- Rilzabrutinib在经治温抗体型AIHA中总体血红蛋白应答率64%,持久应答率80%。
- 安全性可控,治疗相关不良事件多为轻中度恶心和腹泻,无停药或死亡。
- Rilzabrutinib通过多免疫调节可能减少或停用糖皮质激素。
核心结论
- Rilzabrutinib在经治温抗体型自身免疫性溶血性贫血中显示稳健的总体和持久血红蛋白应答及良好安全性。
研究设计与样本
- LUMINA 2为多中心、单臂、开放标签2b期研究,纳入18岁及以上原发性或SLE相关温抗体型AIHA且复发、难治或依赖糖皮质激素的成人。
- 患者来自中国、丹麦、意大利、西班牙、英国和美国15个中心;A部分口服rilzabrutinib 400 mg每日两次共24周,应答者进入B部分持续用药至末例患者完成52周。
主要发现
- A部分22例中14例(64%;95%CI 41-83)达总体血红蛋白应答,其中13例(59%;36-79)为应答、3例(14%;3-35)为完全应答。
- B部分15例中12例(80%)达持久血红蛋白应答。
- A部分治疗相关不良事件10/22例(45%),B部分4/15例(27%);A部分最常见为恶心3例(14%)和腹泻2例(9%)。
- A部分4/22例(18%)发生严重不良事件(流感、肺炎、溶血性贫血、腱鞘炎),均与治疗无关;B部分1例严重贫血被认为与治疗相关,1例血红蛋白下降的严重不良事件与治疗无关。
- 无特别关注的不良事件、导致rilzabrutinib停药的不良事件或死亡。
关键数值与推荐
- A部分主要终点为第24周总体血红蛋白应答:应答指血红蛋白较基线增加≥2 g/dL且溶血未生化缓解;完全应答指女性血红蛋白≥11 g/dL或男性≥12 g/dL且无溶血证据。
- B部分主要终点持久应答指第24周后至第50周连续三次访视血红蛋白至少10 g/dL且较基线增加至少2 g/dL。
- 主要终点评估均无需补救药物或输血。
临床怎么用
- Rilzabrutinib可能为经治温抗体型AIHA提供口服靶向治疗选择,并有机会减少或停用糖皮质激素。
- 治疗期间需监测血红蛋白应答及不良事件,严重不良事件虽多与治疗无关但仍需关注感染等风险。
局限性
- 单臂、开放标签设计,样本量小(A部分22例,B部分15例),无对照组。
- 随访至50周数据截止,长期扩展研究仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Warm autoimmune haemolytic anaemia is a rare blood disorder characterised by haemolysis, anaemia, elevated thromboembolism risk, fatigue, and impaired quality of life. The selective Bruton tyrosine kinase inhibitor, rilzabrutinib, might increase haemoglobin through multi-immune modulatory mechanisms targeting key drivers of warm autoimmune haemolytic anaemia pathophysiology. The aim of the study was to report clinical safety and activity results for rilzabrutinib in patients with warm autoimmune haemolytic anaemia. METHODS: LUMINA 2, a multicentre, single-arm, open-label, phase 2b study, evaluated rilzabrutinib (with or without concomitant corticosteroids) in adults aged 18 years or older with primary or systemic lupus erythematosus-associated warm autoimmune haemolytic anaemia who were relapsed, refractory to, or dependent on corticosteroids. Patients were enrolled in 15 clinical research study centres from China, Denmark, Italy, Spain, the UK, and the USA. Patients in part A received oral rilzabrutinib at 400 mg twice a day for 24 weeks. The part A primary endpoint was overall haemoglobin response by week 24: response (haemoglobin increased by ≥2 g/dL from baseline without biochemical resolution of haemolysis) or complete response (haemoglobin ≥11 g/dL for women or ≥12 g/dL for men with no evidence of haemolysis). Responding patients in part A continued into part B with oral rilzabrutinib at 400 mg twice a day until the last patient completed 52 weeks (eligible patients could continue long-term extension for up to 253 weeks). The part B primary endpoint of durable response was haemoglobin at least 10 g/dL with an increase from baseline of at least 2 g/dL on three consecutive visits from after week 24 to week 50. Primary endpoints were without rescue medication or transfusion. The study is registered with ClinicalTrials.gov (NCT05002777) and EU Clinical Trials Register (2023-509441-13-00); enrolment is complete, analyses conducted at the 50-week data cutoff are provided per protocol, and the long-term extension is continuing. FINDINGS: From Jan 24, 2022, to Dec 6, 2023 (50-week data cutoff for ongoing trial was Nov 21, 2024), 22 patients enrolled in part A and 15 entered part B. 14 (64%; 95% CI 41-83) of 22 patients in part A had overall haemoglobin response (13 [59%; 36-79] response and three [14%; 3-35] complete response). 12 (80%) of 15 patients in part B had durable haemoglobin response. Treatment-related adverse events were observed in ten (45%) of 22 patients in part A and four (27%) of 15 patients in part B. The most common treatment-related adverse events in part A were nausea in three (14%) and diarrhoea in two (9%) of 22 patients. Four (18%) of 22 patients in part A had serious adverse events (ie, influenza, pneumonia, haemolytic anaemia, and tenosynovitis); none were treatment related. One patient in part B had severe anaemia considered related to treatment and one patient had a serious adverse event of decreased haemoglobin unrelated to treatment. There were no adverse events of special interest, leading to rilzabrutinib discontinuation, or deaths. INTERPRETATION: To our knowledge, this is first clinical study of a Bruton tyrosine kinase inhibitor, rilzabrutinib, in warm autoimmune haemolytic anaemia. Rilzabrutinib showed robust overall and durable haemoglobin response and favourable safety in patients with previously treated warm autoimmune haemolytic anaemia. Rilzabrutinib has the potential to treat the underlying pathophysiology of warm autoimmune haemolytic anaemia through multi-immune modulation, induce a robust and sustained haemoglobin response, and provides an opportunity to decrease or stop corticosteroid use. FUNDING: Sanofi.
引用
- Cooper N, Kuter DJ, Frederiksen H, et al. Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2). Lancet Haematol. 2026. PMID: 42822477. doi:10.1016/S2352-3026(26)00218-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。